Anlotinib for Hepatocellular Carcinoma

Liver Neoplasms Clinical Trial

— AFHC  

Official title:

A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Hepatocellular Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04954521
• Other study ID #: KY-QT-201905
• Status: Recruiting
• Start date: June 30, 2021
• Est. completion date: July 5, 2024

Study information

• Verified date: June 2021
• Source: Guangxi Zhuang Autonomous Region People's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in the real world, and to summarize the treatment experience of a wide range of people.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: July 5, 2024
• Est. primary completion date: July 5, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Age: = 18 years old, male or female;

2. Patients with advanced liver cancer were diagnosed;

3. Patients assessed by doctors to benefit from single or combined treatment of arotinib;

4. Patients volunteered to join the project.

Exclusion Criteria:

None

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Liver Neoplasms

Intervention

Drug:
• Anlotinib
This is an observational study

Locations

Country	Name	City	State
China	People's Hospital of Guangxi Zhuang Autonomous Region	Nanning	Guangxi

Sponsors (1)

Lead Sponsor	Collaborator
Guangxi Zhuang Autonomous Region People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	OS	Overall Survival	From date of admission until the date of death from any cause, assessed up to 24 months
Secondary	PFS	Progression Free Survival	From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months